Contact information
natalie.marchevsky@paediatrics.ox.ac.uk
https://orcid.org/0000-0003-1055-0033
Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE
She/her
Natalie Marchevsky
MSc BSc
Senior Medical Statistician
Natalie joined the Oxford Vaccine Group as a Medical Statistician in 2020, where she initially focussed on the Oxford-AstraZeneca COVID-19 vaccine trials. She holds a BSc in Mathematics and Statistics and an MSc in Medical Statistics, and has prior experience working in clinical trials across multiple therapeutic areas including women’s health, coloproctology and colorectal cancer, and primary care research.
In her current role, Natalie works on a diverse portfolio of both adult and paediatric vaccine studies, including COVID-19, measles, MERS-CoV, Nipah virus, plague, and malaria vaccine trials. She also contributes to research examining the optimisation of routine infant vaccine schedules.
Her research interests include childhood immunisation schedules and early phase trials, particularly those targeting emerging pathogens.
Key publications
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
-
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
EWER K. et al, (2021), The Lancet
-
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
Journal article
Voysey M. et al, (2021), The Lancet
Recent publications
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
Journal article
Li G. et al, (2025), Vaccine, 62
-
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil
Journal article
Costa Clemens SA. et al, (2025), Mayo Clinic Proceedings Innovations Quality and Outcomes, 9
-
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
Journal article
Costa Clemens SA. et al, (2023), Hum Vaccin Immunother, 19
-
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Journal article
Mentzer AJ. et al, (2023), Nat Med, 29, 147 - 157
-
A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered With Group B Meningococcal Vaccine.
Journal article
Rajan M. et al, (2022), The Pediatric infectious disease journal, 42, 66 - 73